about
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibRoles of epidemiology, pathology, molecular biology, and biomarkers in the investigation of occupational lung cancerThe role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysisMucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar featuresAmplification of Cellular Oncogenes in Solid TumorsPooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells.Modeling human lung cancer in mice: similarities and shortcomings.Clinical relevance of KRAS in human cancers.Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRASInteraction between smoking and asbestos in human lung adenocarcinoma: role of K-ras mutationsWnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium.Mutation of the LXCXE binding cleft of pRb facilitates transformation by ras in vitro but does not promote tumorigenesis in vivoClinical impact of novel treatment strategies.Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer.Enhancement of lung tumorigenesis in a Gprc5a Knockout mouse by chronic extrinsic airway inflammation.Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinomaTargeting filamin A reduces K-RAS-induced lung adenocarcinomas and endothelial response to tumor growth in mice.Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancerMolecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinomaThe antibiotic azatyrosine suppresses progesterone or [Val12]p21 Ha-ras/insulin-like growth factor I-induced germinal vesicle breakdown and tyrosine phosphorylation of Xenopus mitogen-activated protein kinase in oocytes.Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.Biomarkers in lung cancer: from early detection to novel therapeutics and decision makingReview paper: the role of inflammation in mouse pulmonary neoplasia.Rap2a serves as a potential prognostic indicator of renal cell carcinoma and promotes its migration and invasion through up-regulating p-Akt.Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma.The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras.Wnt and Kras signaling-dark siblings in lung cancer.Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.K-ras activation generates an inflammatory response in lung tumors.Laboratory probing of oncogenes from human liquid and solid specimens as markers of exposure to toxicants.Radiosensitivity of small-cell lung cancer xenografts compared with activity of c-myc, N-myc, L-myc, c-raf-1 and K-ras proto-oncogenes.Inhibitory effect of flavonoids on mutant H-Rasp protein.Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.Lung cancer in women: the differences in epidemiology, biology and treatment outcomes.EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
P2860
Q21563446-802657EA-DA22-4DB4-AF66-1FEED581A20BQ23923155-8D624904-DEE1-4153-89AD-C5A9EB8E0523Q24650902-29E769E2-94CE-498A-95D6-3A352DEEA0E1Q24683814-F53A9DAF-6E69-4AAB-AA0D-BC12E3D60D52Q26784582-19823C09-977B-4E2C-9FE8-F2CAD356B50CQ27313799-CC40AA7F-F2B6-4005-85A0-8B8DB81D9E02Q30877356-F8EF5C60-176D-4677-B280-FA1941D1A5BCQ33739273-F095CF74-530F-4748-9C72-88BE45016075Q33959887-CE0D7775-CBA5-48D2-8707-0AEE31D40400Q34023414-1D616BBD-EB67-497D-BE17-520CCFC93C53Q34857705-9AFDA897-1303-4862-9CC2-AC91BDAC5F78Q34876177-A8D0B5DF-7D7F-4949-9CE3-B1E780F27D9FQ34927226-7D017F31-96D1-4115-B576-A97BFB19E8FEQ34936052-9D3C055D-6F35-4E4D-8952-F7857584B47EQ34963574-E0CC511A-67C2-4A54-951E-C8E96F86517CQ35763410-29EF433E-573E-44DF-9D4F-071A6BD8C177Q35882329-0A3012E8-E22E-4BB2-897F-25270A29765EQ36232402-D7086226-467A-4064-83C1-29F11E0E3F02Q36536565-3C49C976-F3F5-4BCD-8CD6-0A7976A4D200Q36691733-1CEDAAC6-7844-4734-ABCA-E9BF8C26EEF9Q36946809-4E671D71-748A-436C-8459-FB1FF358BE90Q36952283-C5A24D79-A3C5-4B71-A3E4-866259D01637Q36972803-D4CEBD8B-94B3-4411-93CD-4A74166916A4Q37158504-FE5931EF-5923-44DC-94C1-181A99DC2F5FQ37226800-75F3FD45-374B-4B70-8D52-85F90855BC5CQ37229930-5E662E49-D7D6-4EB7-8141-0ACFA4974B4AQ37342919-2F928695-70A9-49F8-8AE1-06D133EE43B4Q37379547-4485E0A6-8426-40DF-B095-22EE9F065DB7Q38659246-12C0BC28-787E-4FAE-802B-3709F24C1FC7Q39442031-12A4588D-358C-49BC-9CAB-F786285F8615Q39473621-FFBC6703-936F-4352-80CD-B9D0A1FD53FFQ39507181-0020DF48-A21E-49C0-96AB-C81738203FF6Q39635376-80A66187-98DE-4C99-9FAF-BA1362EEC538Q40351368-54E36ABB-2CA2-4029-B00D-FF3E4040B209Q41188296-6823A752-8AD2-4ACD-9E4F-7863EBC30C9CQ41665634-BEB84C19-1479-4BD8-9E84-FE8F11FE09BFQ42606981-E8967BF6-49A2-48E3-8645-E6F0751FF2C4Q42828044-096A368D-CDCE-4337-8175-A5944961A8EEQ44477692-D8B7572E-48C1-43E2-990A-2310C6AAED82Q46640557-2CF3F668-8BBB-49CE-8B45-0368E85784E9
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The ras oncogenes in human lung cancer.
@en
type
label
The ras oncogenes in human lung cancer.
@en
prefLabel
The ras oncogenes in human lung cancer.
@en
P356
P1476
The ras oncogenes in human lung cancer.
@en
P2093
Rodenhuis S
P304
P356
10.1164/AJRCCM/142.6_PT_2.S27
P433
P577
1990-12-01T00:00:00Z